SFK inhibitors block PGE2-induced EGFR nuclear translocation, as do ADAM and MMP inhibitors, suggesting that EGF-like ligands are shedded in NSCLC cells treated with PGE2. Here, EGFR is linked to non-small cell lung carcinoma.